Globus Medical (GMED) EBIT Margin (2011 - 2026)

Globus Medical has reported EBIT Margin for 16 years, with the latest figure at 19.79% in Q1 2026.

• For the quarter ending Q1 2026, EBIT Margin rose 357.0% year-over-year to 19.79%; the trailing twelve-month figure through Mar 2026 stood at 17.2% (up 704.0% YoY), and the FY2025 full-year result was 16.33%, up 974.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 19.79%, down from 20.49% in the prior quarter.
• The five-year high for EBIT Margin was 25.71% in Q2 2022, with the low at 0.11% in Q3 2023.
• Historically, EBIT Margin has averaged 14.38% across 5 years, with a median of 17.86% in 2025.
• Annual changes were most pronounced in 2023 — EBIT Margin sank 2339 bps — and 2025, when it jumped 1490 bps.
• Globus Medical's EBIT Margin stood at 19.68% in 2022, then tumbled by 92 bps to 1.64% in 2023, then surged by 458 bps to 9.17% in 2024, then jumped by 123 bps to 20.49% in 2025, then decreased by 3 bps to 19.79% in 2026.
• The last three EBIT Margin figures came in at 19.79% (Q1 2026), 20.49% (Q4 2025), and 17.86% (Q3 2025), per Business Quant data.